NanoLogix, Inc. Announces The Successful Conversion Of Welch's Waste Stream Into Usable Hydrogen
SHARON, Pa., May 10 /PRNewswire-FirstCall/ -- NanoLogix, Inc. announced today that hydrogen has been generated at its first commercial scaled-up hydrogen bioreactor facility at a Welch Food's plant in North East, Pennsylvania. The company previously announced the construction of the facility and its intent to begin hydrogen generation from Welch's waste organic matter.
The dependence upon fossil fuels is drawing to a close with the achievement of alternative fuel from waste streams from manufacturing facilities worldwide.
The technology behind the hydrogen bioreactor, developed and proprietary to NanoLogix, is intended to enable manufacturing facilities to convert their waste stream into hydrogen. The alternative energy source then can be converted, on-site, to electricity, thus contributing immediately to the manufacturing facilities bottom line.
David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company (http://www.patriotlift.com) and who spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering operations, commented that, "The generation of hydrogen demonstrates NanoLogix's capability to convert its prolific intellectual property portfolio into needed technologies."
David C. McClelland, President of NanoLogix, commented, "The success NanoLogix has had in converting the waste stream at Welch's into hydrogen is indicative of the extremely exciting possibilities for continuous generation of hydrogen in the future."
Professor Rick Diz of Gannon University, the lead scientist in the project and consultant to NanoLogix stated, "I am pleased to confirm the bioreactor at Welch's is producing hydrogen. Gas chromatography confirmed hydrogen and no methane."
About NanoLogix, Inc.
NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nanologix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.NanoLogix, Inc.
CONTACT: NanoLogix, Inc., +1-724-346-1302